GOA Therapeutics bolsters its clinical development pipeline by hiring a veteran executive with extensive experience in drug launches and medical affairs to serve as Chief Medical Officer.
The appointment of a new Chief Medical Officer with 40 years of industry experience, including a leadership role in Gilead's remdesivir launch, significantly bolsters the company's executive team. This strategic hire is expected to leverage deep expertise in clinical practice and drug development to accelerate the company's pipeline and therapeutic launches.
The new CMO has 40 years of experience in clinical practice, drug development, and medical affairs, most notably leading U.S. Medical Affairs for Gilead's remdesivir launch.
Mention of Gilead as former employer of the new CMO has no direct impact on Gilead's operations or financials.
GOA Therapeutics strengthens its leadership team with the appointment of a seasoned biopharma executive to the role of Chief Medical Officer. The new appointee brings four decades of experience, including a pivotal tenure leading U.S. Medical Affairs for Gilead Sciences during the launch of remdesivir.
The appointment brings deep expertise in clinical practice and drug development, which is expected to accelerate the company's clinical development and therapy launch capabilities.